Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
出版年份 2021 全文链接
标题
Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
作者
关键词
-
出版物
Frontiers in Immunology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-05-07
DOI
10.3389/fimmu.2021.661737
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
- (2020) Paolo A. Ascierto et al. EUROPEAN JOURNAL OF CANCER
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
- (2020) P. Nathan et al. ANNALS OF ONCOLOGY
- Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma
- (2020) Reinhard Dummer et al. JAMA Oncology
- Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
- (2020) H. Gogas et al. ANNALS OF ONCOLOGY
- Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma
- (2020) Emily J. Lelliott et al. Cancer Immunology Research
- Targeting the ERK Signaling Pathway in Melanoma
- (2019) Paola Savoia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- BRAF targeting sensitizes resistant melanoma to cytotoxic T cells
- (2019) Cigdem Atay et al. CLINICAL CANCER RESEARCH
- Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
- (2019) Melvyn T. Chow et al. IMMUNITY
- Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies
- (2019) Stephen A. Luebker et al. Frontiers in Oncology
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
- (2019) Chune Yu et al. Frontiers in Immunology
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
- (2019) Imran G. House et al. CLINICAL CANCER RESEARCH
- Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
- (2019) Antoni Ribas et al. CLINICAL CANCER RESEARCH
- Trends in clinical development for PD-1/PD-L1 inhibitors
- (2019) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
- (2019) Qing-Qing Chai et al. Frontiers in Pharmacology
- Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
- (2019) Dan A. Erkes et al. Cancer Discovery
- Development of encorafenib for BRAF-mutated advanced melanoma
- (2018) Peter Koelblinger et al. CURRENT OPINION IN ONCOLOGY
- Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
- (2018) Claire A. Martin et al. INTERNATIONAL JOURNAL OF CANCER
- Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
- (2018) Reinhard Dummer et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitors of the PD-1 Pathway in Tumor Therapy
- (2018) Martin W. LaFleur et al. JOURNAL OF IMMUNOLOGY
- ERK Inhibition: A New Front in the War against MAPK Pathway–Driven Cancers?
- (2018) Inna Smalley et al. Cancer Discovery
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
- (2018) Meghan J. Mooradian et al. OncoImmunology
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
- (2018) Xin Jin et al. MOLECULAR CELL
- Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
- (2018) Danbee Ha et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
- (2017) Ester Simeone et al. OncoImmunology
- Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
- (2016) A. Yoshida et al. CANCER RESEARCH
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
- (2016) Georgina V Long et al. LANCET ONCOLOGY
- Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways
- (2016) Amanda Tse et al. PLoS One
- Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
- (2016) Giuseppe Argenziano et al. OncoTargets and Therapy
- Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
- (2016) Michael S. Lee et al. Oncotarget
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
- (2016) Marcel A. Deken et al. OncoImmunology
- Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
- (2016) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
- (2015) T. Wang et al. CLINICAL CANCER RESEARCH
- Overall survival in patients with metastatic melanoma
- (2015) Xue Song et al. CURRENT MEDICAL RESEARCH AND OPINION
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
- (2015) David R. Minor et al. Pigment Cell & Melanoma Research
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Anti–PD-1 Therapy in Melanoma
- (2015) Blanca Homet Moreno et al. SEMINARS IN ONCOLOGY
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
- (2015) Blanca Homet Moreno et al. OncoImmunology
- Vemurafenib and ipilimumab: A promising combination? Results of a case series
- (2015) Jessica C. Hassel et al. OncoImmunology
- Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
- (2014) John C Castle et al. BMC GENOMICS
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- (2014) Allison Ackerman et al. CANCER
- Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged
- (2014) Paul B. Chapman et al. CANCER CELL
- Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
- (2014) L. Ferrari de Andrade et al. CANCER RESEARCH
- Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
- (2014) K. M. Ilieva et al. MOLECULAR CANCER THERAPEUTICS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Cellular senescence: from physiology to pathology
- (2014) Daniel Muñoz-Espín et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
- (2014) L. J. Vella et al. Cancer Immunology Research
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
- (2013) K. E. Sheppard et al. CLINICAL CANCER RESEARCH
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
- (2013) M. K. Callahan et al. Cancer Immunology Research
- Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells
- (2013) Bishu Sapkota et al. OncoImmunology
- Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
- (2012) X. Tai et al. BLOOD
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Role of Cdk4 in lymphocyte function and allergen response
- (2011) Yu Hua Chow et al. CELL CYCLE
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
- (2011) E. R. Cantwell-Dorris et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
- (2010) Jean-Philippe Coppé et al. Annual Review of Pathology-Mechanisms of Disease
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?
- (2010) Yohannes Mebratu et al. CELL CYCLE
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Melanocytes are deficient in repair of oxidative DNA damage and UV-induced photoproducts
- (2010) H.-T. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epidemiology of invasive cutaneous melanoma
- (2009) R. M. MacKie et al. ANNALS OF ONCOLOGY
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started